ALIROCUMAB TREATMENT IN A REAL WORLD SETTING: SAFETY UPDATE FROM AN OPEN-LABEL TREATMENT EXTENSION TO THE ODYSSEY PROGRAM FOR PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA

Background: The ODYSSEY open-label extension (OLE) study (NCT01954394) of 4 Phase 3 trials (FH I; FH II; LONG TERM; HIGH FH) is assessing the long-term efficacy and safety of alirocumab (ALI) in patients with heterozygous familial hypercholesterolemia (HeFH) for up to 3.5yrs.

Saved in:
Bibliographic Details
Published in:Journal of the American College of Cardiology 2017-03, Vol.69 (11), p.1660-1660
Main Authors: Guyton, John R, Hovingh, G. Kees, Langslet, Gisle, Dufour, Robert, Baccara-Dinet, Marie, Din-Bell, Chantal, Manvelian, Garen, Farnier, Michel
Format: Article
Language:English
Subjects:
Cardiology
Cardiovascular
Internal Medicine
Long term
Studies
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: The ODYSSEY open-label extension (OLE) study (NCT01954394) of 4 Phase 3 trials (FH I; FH II; LONG TERM; HIGH FH) is assessing the long-term efficacy and safety of alirocumab (ALI) in patients with heterozygous familial hypercholesterolemia (HeFH) for up to 3.5yrs.
ISSN:0735-1097
1558-3597
DOI:10.1016/S0735-1097(17)35049-0